Syndax Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) is a commercial-stage biopharmaceutical company founded in 2005 and headquartered in New York, NY. The company is dedicated to developing and commercializing a pipeline of targeted cancer therapies and treatments for serious immune-mediated diseases. Syndax transitioned from a clinical-stage biotech to a commercial-stage player following the landmark FDA approvals of its two lead assets: Revuforj (revumenib), an oral menin inhibitor approved for adult and pediatric patients with relapsed or refractory acute leukemia harboring KMT2A translocations or NPM1 mutations, and Niktimvo (axatilimab-csfr), a monoclonal antibody targeting the CSF-1 receptor approved for chronic graft-versus-host disease (cGVHD) after multiple prior lines of systemic therapy.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing Revuforj (revumenib) into frontline treatment settings for newly diagnosed NPM1-mutated and KMT2A-rearranged acute myeloid leukemia (AML) through pivotal global clinical trials.
Expected impact: Aims to establish Revuforj as the first-to-frontline menin inhibitor, unlocking a multi-billion-dollar addressable market opportunity.
Expanding the clinical footprint of Niktimvo (axatilimab) into earlier lines of therapy for chronic graft-versus-host disease (cGVHD) in combination with ruxolitinib (Jakafi) and steroids, as well as other fibrotic diseases like Idiopathic Pulmonary Fibrosis (IPF).
Expected impact: Aims to maximize the commercial potential of the CSF-1R franchise by moving into frontline combination regimens and new indications.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Collaborating on the global development and commercialization of Niktimvo (axatilimab) in cGVHD and any future indications.
Terms: Incyte leads global commercialization activities. The companies share 50/50 profits in the U.S., and Syndax receives double-digit royalties on net sales outside the U.S. Syndax co-promotes the product in the U.S.
Expanding international patient access to Revuforj (revumenib) in regions outside the U.S. where the drug is not yet commercially approved but local regulations permit access.
Terms: WODA administers the program and coordinates named-patient supply through its global network across Eurasia, Central and Southeast Europe, Israel, the Middle East, Turkey, Latin America, and Africa.